Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2013, Article ID 946427, 15 pages
http://dx.doi.org/10.1155/2013/946427
Review Article

Visfatin/Nampt: An Adipokine with Cardiovascular Impact

1Paul-Langerhans Group of Integrative Physiology, German Diabetes Center, Auf'm Hennekamp 65, 40225 Düsseldorf, Germany
2Departamento de Farmacología y Terapéutica, Facultad de Medicina, Universidad Autónoma de Madrid, Arzobispo Morcillo 4, 28029 Madrid, Spain

Received 1 April 2013; Accepted 20 May 2013

Academic Editor: Assaf Rudich

Copyright © 2013 Tania Romacho et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Boucher, B. Masri, D. Daviaud et al., “Apelin, a newly identified adipokine up-regulated by insulin and obesity,” Endocrinology, vol. 146, no. 4, pp. 1764–1771, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Fukuhara, M. Matsuda, M. Nishizawa et al., “Visfatin: a protein secreted by visceral fat that Mimics the effects of insulin,” Science, vol. 307, no. 5708, pp. 426–430, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Lamers, S. Famulla, N. Wronkowitz et al., “Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome,” Diabetes, vol. 60, no. 7, pp. 1917–1925, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. C. M. Steppan, S. T. Bailey, S. Bhat et al., “The hormone resistin links obesity to diabetes,” Nature, vol. 409, no. 6818, pp. 307–312, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Fukuhara, M. Matsuda, M. Nishizawa et al., “Retraction,” Science, vol. 318, no. 5850, p. 565, 2007. View at Google Scholar
  6. B. Samal, Y. Sun, G. Stearns, C. Xie, S. Suggs, and I. McNiece, “Cloning and characterization of the cDNA encoding a novel human pre-B- cell colony-enhancing factor,” Molecular and Cellular Biology, vol. 14, no. 2, pp. 1431–1437, 1994. View at Google Scholar · View at Scopus
  7. J. Berndt, N. Klöting, S. Kralisch et al., “Plasma visfatin concentrations and fat depot-specific mRNA expression in humans,” Diabetes, vol. 54, no. 10, pp. 2911–2916, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. B. K. Tan, J. Chen, J. E. Digby, S. D. Keay, C. R. Kennedy, and H. S. Randeva, “Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 12, pp. 5022–5028, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. K. H. Cheng, C.S. Chu, K.T. Lee et al., “Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease,” International Journal of Obesity, vol. 32, no. 2, pp. 268–274, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Wang, T. Xu, Y. Guan, D. Su, G. Fan, and C. Miao, “Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide,” Cardiovascular Research, vol. 81, no. 2, pp. 370–380, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. C. A. Curat, V. Wegner, C. Sengenès et al., “Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin,” Diabetologia, vol. 49, no. 4, pp. 744–747, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Rongvaux, R. J. Shea, M. H. Mulks et al., “Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis,” European Journal of Immunology, vol. 32, no. 11, pp. 3225–3234, 2002. View at Google Scholar
  13. L. Formentini, F. Moroni, and A. Chiarugi, “Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo,” Biochemical Pharmacology, vol. 77, no. 10, pp. 1612–1620, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. R. Revollo, A. A. Grimm, and S. Imai, “The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells,” Journal of Biological Chemistry, vol. 279, no. 49, pp. 50754–50763, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Ho, E. van der Veer, O. Akawi, and J. G. Pickering, “SIRT1 markedly extends replicative lifespan if the NAD+ salvage pathway is enhanced,” FEBS Letters, vol. 583, no. 18, pp. 3081–3085, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. E. van der Veer, Z. Nong, C. O'Neil, B. Urquhart, D. Freeman, and J. G. Pickering, “Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation,” Circulation Research, vol. 97, no. 1, pp. 25–34, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. E. van der Veer, C. Ho, C. O'Neil et al., “Extension of human cell lifespan by nicotinamide phosphoribosyltransferase,” Journal of Biological Chemistry, vol. 282, no. 15, pp. 10841–10845, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. J. R. Revollo, A. Korner, K. F. Mills et al., “Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme,” Cell Metabolism, vol. 6, no. 5, pp. 363–375, 2007. View at Publisher · View at Google Scholar
  19. S. Imai, “Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases,” Current Pharmaceutical Design, vol. 15, no. 1, pp. 20–28, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Pilz, H. Mangge, B. Obermayer-Pietsch, and W. März, “Visfatin/pre-B-cell colony-enhancing factor: a protein with various suggested functions,” Journal of Endocrinological Investigation, vol. 30, no. 2, pp. 138–144, 2007. View at Google Scholar · View at Scopus
  21. J. M. Stephens and A. J. Vidal-Puig, “An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity,” Current Opinion in Lipidology, vol. 17, no. 2, pp. 128–131, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Gosset, F. Berenbaum, C. Salvat et al., “Crucial role of visfatin/pre-B cell colony-enhancing factor in matrix degradation and prostaglandin E2 synthesis in chondrocytes: possible influence on osteoarthritis,” Arthritis and Rheumatism, vol. 58, no. 5, pp. 1399–1409, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Ognjanovic, T. L. Ku, and G. D. Bryant-Greenwood, “Pre-B-cell colony-enhancing factor is a secreted cytokine-like protein from the human amniotic epithelium,” American Journal of Obstetrics and Gynecology, vol. 193, no. 1, pp. 273–282, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. S. R. Costford, S. Bajpeyi, M. Pasarica et al., “Skeletal muscle NAMPT is induced by exercise in humans,” American Journal of Physiology, vol. 298, no. 1, pp. E117–E126, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Garten, S. Petzold, A. Barnikol-Oettler et al., “Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes,” Biochemical and Biophysical Research Communications, vol. 391, no. 1, pp. 376–381, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Frydelund-Larsen, T. Akerstrom, S. Nielsen, P. Keller, C. Keller, and B. K. Pedersen, “Visfatin mRNA expression in human subcutaneous adipose tissue is regulated by exercise,” American Journal of Physiology, vol. 292, no. 1, pp. E24–E31, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Kukla, M. Ciupińska-Kajor, M. Kajor et al., “Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery,” Polish Journal of Pathology, vol. 61, no. 3, pp. 147–153, 2010. View at Google Scholar · View at Scopus
  28. M. P. Chen, F. M. Chung, D. M. Chang et al., “Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 1, pp. 295–299, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. T. D. Filippatos, C. S. Derdemezis, I. F. Gazi et al., “Increased plasma visfatin levels in subjects with the metabolic syndrome,” European Journal of Clinical Investigation, vol. 38, no. 1, pp. 71–72, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Sommer, A. Garten, S. Petzold et al., “Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine,” Clinical Science, vol. 115, no. 1, pp. 13–23, 2008. View at Publisher · View at Google Scholar
  31. P. M. Vanhoutte, “Endothelial dysfunction: the first step toward coronary arteriosclerosis,” Circulation Journal, vol. 73, no. 4, pp. 595–601, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Takebayashi, M. Suetsugu, S. Wakabayashi, Y. Aso, and T. Inukai, “Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus,” Metabolism, vol. 56, no. 4, pp. 451–458, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Uslu, N. Kebapci, M. Kara et al., “Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus,” Experimental and Therapeutic Medicine, vol. 4, no. 1, pp. 113–120, 2012. View at Google Scholar
  34. F. Stam, C. van Guldener, C. G. Schalkwijk et al., “Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity,” Nephrology Dialysis Transplantation, vol. 18, no. 5, pp. 892–898, 2003. View at Publisher · View at Google Scholar
  35. N. P. E. Kadoglou, N. Sailer, A. Moumtzouoglou et al., “Visfatin (Nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes,” Experimental and Clinical Endocrinology and Diabetes, vol. 118, no. 2, pp. 75–80, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. A. E. Malavazos, F. Ermetici, E. Cereda et al., “Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 18, no. 8, pp. 523–530, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Fasshauer, T. Waldeyer, J. Seeger et al., “Serum levels of the adipokine visfatin are increased in pre-eclampsia,” Clinical Endocrinology, vol. 69, no. 1, pp. 69–73, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Tan, M. Zhong, H. Gong, S. Wang, Y. Zhang, and W. Zhang, “Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis,” Clinical Endocrinology, vol. 69, no. 6, pp. 878–884, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. C. E. Pepene, “Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome,” Clinical Endocrinology, vol. 76, no. 1, pp. 119–125, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. S. W. Liu, S. B. Qiao, J. S. Yuan, and D. Q. Liu, “Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans,” Clinical Endocrinology, vol. 71, no. 2, pp. 202–207, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. M. I. Yilmaz, M. Saglam, J. J. Carrero et al., “Serum visfatin concentration and endothelial dysfunction in chronic kidney disease,” Nephrology Dialysis Transplantation, vol. 23, no. 3, pp. 959–965, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Axelsson, A. Witasp, J. J. Carrero et al., “Circulating levels of Visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD,” American Journal of Kidney Diseases, vol. 49, no. 2, pp. 237–244, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Malyszko, J. S. Malyszko, and M. Mysliwiec, “Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney allograft recipients,” Transplantation Proceedings, vol. 41, no. 1, pp. 150–153, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Malyszko, J. S. Malyszko, K. Pawlak, and M. Mysliwiec, “Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure,” Advances in Medical Sciences, vol. 53, pp. 32–36, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Kato, M. Odamaki, J. Ishida, and A. Hishida, “Relationship between serum Pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients,” American Journal of Nephrology, vol. 29, no. 1, pp. 31–35, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. M. I. Yilmaz, M. Saglam, J. J. Carrero et al., “Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage?” Clinical Transplantation, vol. 23, no. 2, pp. 241–248, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. L. F. Lu, S. S. Yang, C. P. Wang et al., “Elevated Visfatin/Pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke,” Journal of Stroke and Cerebrovascular Diseases, vol. 18, no. 5, pp. 354–359, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. T. H. Yu, L. F. Lu, W. C. Hung et al., “Circulating visfatin level at admission is associated with occlusion of the infarct-related artery in patients with acute ST-segment elevation myocardial infarction,” Acta Cardiologica Sinica, vol. 27, no. 2, pp. 77–85, 2011. View at Google Scholar · View at Scopus
  49. L. F. Lu, C. P. Wang, T. H. Yu et al., “Interpretation of elevated plasma visfatin concentrations in patients with ST-elevation myocardial infarction,” Cytokine, vol. 57, no. 1, pp. 74–80, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Laudes, F. Oberhauser, D. M. Schulte et al., “Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans,” Hormone and Metabolic Research, vol. 42, no. 4, pp. 268–273, 2010. View at Publisher · View at Google Scholar
  51. K. Oki, K. Yamane, N. Kamei, H. Nojima, and N. Kohno, “Circulating visfatin level is correlated with inflammation, but not with insulin resistance,” Clinical Endocrinology, vol. 67, no. 5, pp. 796–800, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. F. L. Brancati, P. K. Whelton, B. L. Randall, J. D. Neaton, J. Stamler, and M. J. Klag, “Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT,” Journal of the American Medical Association, vol. 278, no. 23, pp. 2069–2074, 1997. View at Google Scholar · View at Scopus
  53. L. L. Humphrey, D. J. Ballard, P. P. Frohnert, C.P. Chu, M. O'Fallon, and P. J. Palumbo, “Chronic renal failure in non-insulin-dependent diabetes mellitus. A population-based study in Rochester, Minnesota,” Annals of Internal Medicine, vol. 111, no. 10, pp. 788–796, 1989. View at Google Scholar · View at Scopus
  54. I. Kowalska, M. Straczkowski, A. Nikolajuk et al., “Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome,” Human Reproduction, vol. 22, no. 7, pp. 1824–1829, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. E. A. Steegers, P. von Dadelszen, J. J. Duvekot, and R. Pijnenborg, “Pre-eclampsia,” The Lancet, vol. 376, no. 9741, pp. 631–644, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. A. F. Ferreira, J. C. Rezende, C. O. R. de Cassia et al., “Maternal serum visfatin at 11–13 weeks' gestation in preeclampsia,” Journal of Human Hypertension, vol. 27, no. 4, pp. 261–264, 2013. View at Publisher · View at Google Scholar
  57. E. Zulfikaroglu, F. Isman, A. PayaslI, S. KIlIc, M. Kucur, and N. DanIsman, “Plasma visfatin levels in preeclamptic and normal pregnancies,” Archives of Gynecology and Obstetrics, vol. 281, no. 6, pp. 995–998, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. W. Hu, Z. Wang, H. Wang, H. Huang, and M. Dong, “Serum visfatin levels in late pregnancy and pre-eclampsia,” Acta Obstetricia et Gynecologica Scandinavica, vol. 87, no. 4, pp. 413–418, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. S. C. Kim, M. J. Park, B. S. Joo et al., “Decreased expressions of vascular endothelial growth factor and visfatin in the placental bed of pregnancies complicated by preeclampsia,” Journal of Obstetrics and Gynaecology Research, vol. 38, no. 4, pp. 665–673, 2012. View at Publisher · View at Google Scholar
  60. J. M. Roberts and D. W. Cooper, “Pathogenesis and genetics of pre-eclampsia,” The Lancet, vol. 357, no. 9249, pp. 53–56, 2001. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Ognjanovic and G. D. Bryant-Greenwood, “Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes,” American Journal of Obstetrics and Gynecology, vol. 187, no. 4, pp. 1051–1058, 2002. View at Publisher · View at Google Scholar · View at Scopus
  62. T. D. Filippatos, H. S. Randeva, C. S. Derdemezis et al., “Visfatin/PBEF and atherosclerosis-related diseases,” Current Vascular Pharmacology, vol. 8, no. 1, pp. 12–28, 2010. View at Publisher · View at Google Scholar
  63. T. B. Dahl, A. Yndestad, M. Skjelland et al., “Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization,” Circulation, vol. 115, no. 8, pp. 972–980, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. S. G. Spiroglou, C. G. Kostopoulos, J. N. Varakis, and H. H. Papadaki, “Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis,” Journal of Atherosclerosis and Thrombosis, vol. 17, no. 2, pp. 115–130, 2010. View at Google Scholar · View at Scopus
  65. P. Wang, P. M. Vanhoutte, and C. Y. Miao, “Visfatin and cardio-cerebro-vascular disease,” Journal of Cardiovascular Pharmacology, vol. 59, no. 1, pp. 1–9, 2011. View at Google Scholar
  66. L. Y. Liu, F. Wang, X. Y. Zhang et al., “Nicotinamide phosphoribosyltransferase may be involved in age-related brain diseases,” PLoS One, vol. 7, no. 10, Article ID e44933, 2012. View at Google Scholar
  67. F. Brentano, O. Schorr, C. Ospelt et al., “Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities,” Arthritis and Rheumatism, vol. 56, no. 9, pp. 2829–2839, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. M. A. Nowell, P. J. Richards, C. A. Fielding et al., “Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 54, no. 7, pp. 2084–2095, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. A. R. Moschen, A. Kaser, B. Enrich et al., “Visfatin, an adipocytokine with proinflammatory and immunomodulating properties,” Journal of Immunology, vol. 178, no. 3, pp. 1748–1758, 2007. View at Google Scholar · View at Scopus
  70. S. Q. Ye, B. A. Simon, J. P. Maloney et al., “Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury,” American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 4, pp. 361–370, 2005. View at Publisher · View at Google Scholar
  71. S. H. Jia, Y. Li, J. Parodo et al., “Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis,” Journal of Clinical Investigation, vol. 113, no. 9, pp. 1318–1327, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Ognjanovic, S. Bao, S. Y. Yamamoto, J. Garibay-Tupas, B. Samal, and G. D. Bryant-Greenwood, “Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes,” Journal of Molecular Endocrinology, vol. 26, no. 2, pp. 107–117, 2001. View at Publisher · View at Google Scholar · View at Scopus
  73. B. Mesko, S. Poliska, A. Szegedi et al., “Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets,” BMC Medical Genomics, vol. 3, p. 15, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. L. Senolt, O. Krystufkova, H. Hulejova et al., “The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy,” Cytokine, vol. 55, no. 1, pp. 116–121, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Gerdes, S. Osadtschy, M. Rostami-Yazdi et al., “Leptin, adiponectin, visfatin and retinol-binding protein-4-mediators of comorbidities in patients with psoriasis?” Experimental Dermatology, vol. 21, no. 1, pp. 43–47, 2012. View at Publisher · View at Google Scholar
  76. M. Scotece, J. Conde, R. Gomez et al., “Role of adipokines in atherosclerosis: interferences with cardiovascular complications in rheumatic diseases,” Mediators of Inflammation, vol. 2012, Article ID 125458, 2012. View at Publisher · View at Google Scholar
  77. K. S. Moulton, “Angiogenesis in atherosclerosis: gathering evidence beyond speculation,” Current Opinion in Lipidology, vol. 17, no. 5, pp. 548–555, 2006. View at Publisher · View at Google Scholar
  78. R. Adya, B. K. Tan, A. Punn, J. Chen, and H. S. Randeva, “Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis,” Cardiovascular Research, vol. 78, no. 2, pp. 356–365, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. S. R. Kim, S. K. Bae, K. S. Choi et al., “Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2,” Biochemical and Biophysical Research Communications, vol. 357, no. 1, pp. 150–156, 2007. View at Publisher · View at Google Scholar
  80. F. Lovren, Y. Pan, P. C. Shukla et al., “Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis,” American Journal of Physiology, vol. 296, no. 6, pp. E1440–E1449, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. J. Xiao, Z. Xiao, Z. Liu et al., “Involvement of dimethylarginine dimethylaminohydrolase-2 in visfatin-enhanced angiogenic function of endothelial cells,” Diabetes/Metabolism Research and Reviews, vol. 25, no. 3, pp. 242–249, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. R. Adya, B. K. Tan, J. Chen, and H. S. Randeva, “Pre-B cell colony enhancing factor (PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells: role in visfatin-induced angiogenesis,” Atherosclerosis, vol. 205, no. 1, pp. 113–119, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. Y. Bae, M. Bae, S. Kim, J. H. Lee, H. Wee, and S. Bae, “Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis,” Biochemical and Biophysical Research Communications, vol. 379, no. 2, pp. 206–211, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. W. J. Lee, C. S. Wu, H. Lin et al., “Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway,” International Journal of Obesity, vol. 33, no. 4, pp. 465–472, 2009. View at Publisher · View at Google Scholar
  85. S. R. Kim, Y. H. Jung, H. J. Park et al., “Upregulation of thromboxane synthase mediates visfatin-induced interleukin-8 expression and angiogenic activity in endothelial cells,” Biochemical and Biophysical Research Communications, vol. 418, no. 4, pp. 662–668, 2012. View at Publisher · View at Google Scholar
  86. W. Zhang, Y. Xie, T. Wang et al., “Neuronal protective role of PBEF in a mouse model of cerebral ischemia,” Journal of Cerebral Blood Flow and Metabolism, vol. 30, no. 12, pp. 1962–1971, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. W. Tian, Y. Zhu, Y. Wang et al., “Visfatin, a potential biomarker and prognostic factor for endometrial cancer,” Gynecologic Oncology, vol. 129, no. 3, pp. 505–512, 2013. View at Publisher · View at Google Scholar
  88. M. S. Fazeli, H. Dashti, S. Akbarzadeh et al., “Circulating levels of novel adipocytokines in patients with colorectal cancer,” Cytokine, vol. 62, no. 1, pp. 81–85, 2013. View at Publisher · View at Google Scholar
  89. T. E. Nakajima, Y. Yamada, T. Hamano et al., “Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer,” Journal of Gastroenterology, vol. 44, no. 7, pp. 685–690, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. F. Montecucco, M. Cea, I. Bauer et al., “Nicotinamide phosphoribosyltransferase (Nampt) inhibitors as therapeutics: rationales, controversies, clinical experience,” Current Drug Targets, vol. 14, no. 6, pp. 637–643, 2013. View at Google Scholar
  91. A. Pogrebniak, I. Schemainda, K. Azzam et al., “Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents,” European Journal of Medical Research, vol. 11, no. 8, pp. 313–321, 2006. View at Google Scholar
  92. A. Ravaud, T. Cerny, C. Terret et al., “Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study,” European Journal of Cancer, vol. 41, no. 5, pp. 702–707, 2005. View at Publisher · View at Google Scholar · View at Scopus
  93. X. Y. Yu, S. B. Qiao, H. S. Guan et al., “Effects of visfatin on proliferation and collagen synthesis in rat cardiac fibroblasts,” Hormone and Metabolic Research, vol. 42, no. 7, pp. 507–513, 2010. View at Publisher · View at Google Scholar
  94. V. B. Pillai, N. R. Sundaresan, G. Kim et al., “Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling,” American Journal of Physiology, vol. 304, no. 3, pp. 415–426, 2013. View at Publisher · View at Google Scholar
  95. Y. Li, Y. Zhang, B. Dorweiler et al., “Extracellular nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism,” Journal of Biological Chemistry, vol. 283, no. 50, pp. 34833–34843, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. T. Romacho, V. Azcutia, M. Vázquez-Bella et al., “Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity,” Diabetologia, vol. 52, no. 11, pp. 2455–2463, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. S. R. Kim, Y. H. Bae, S. K. Bae et al., “Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells,” Biochimica et Biophysica Acta, vol. 1783, no. 5, pp. 886–895, 2008. View at Publisher · View at Google Scholar
  98. S. W. Liu, S. B. Qiao, J. S. Yuan, and D. Q. Liu, “Visfatin stimulates production of monocyte chemotactic protein-1 and interleukin-6 in human vein umbilical endothelial cells,” Hormone and Metabolic Research, vol. 41, no. 4, pp. 281–286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. R. Adya, B. K. Tan, J. Chen, and H. S. Randeva, “Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells,” Diabetes Care, vol. 31, no. 4, pp. 758–760, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. S. Vallejo, T. Romacho, J. Angulo et al., “Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity,” PLoS One, vol. 6, no. 11, Article ID e27299, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. K. M. Boini, C. Zhang, M. Xia et al., “Visfatin-induced lipid raft redox signaling platforms and dysfunction in glomerular endothelial cells,” Biochimica et Biophysica Acta, vol. 1801, no. 12, pp. 1294–1304, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. M. Xia, C. Zhang, K. M. Boini, A. M. Thacker, and P. Li, “Membrane raftlysosome redox signalling platforms in coronary endothelial dysfunction induced by adipokine visfatin,” Cardiovascular Research, vol. 89, no. 2, pp. 401–409, 2011. View at Publisher · View at Google Scholar · View at Scopus
  103. F. Zhou, Y. Pan, Z. Huang et al., “Visfatin induces cholesterol accumulation in macrophages through up-regulation of scavenger receptor-A and CD36,” Cell Stress and Chaperones, 2013. View at Publisher · View at Google Scholar
  104. P. Pacher, I. G. Obrosova, J. G. Mabley, and C. Szabó, “Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies,” Current Medicinal Chemistry, vol. 12, no. 3, pp. 267–275, 2005. View at Google Scholar · View at Scopus
  105. E. Galkina and K. Ley, “Vascular adhesion molecules in atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, pp. 2292–2301, 2007. View at Publisher · View at Google Scholar
  106. R. M. Touyz and A. M. Briones, “Reactive oxygen species and vascular biology: implications in human hypertension,” Hypertension Research, vol. 34, no. 1, pp. 5–14, 2011. View at Publisher · View at Google Scholar · View at Scopus
  107. M. Xia, C. Zhang, K. M. Boini, A. M. Thacker, and P. Li, “Membrane raftlysosome redox signalling platforms in coronary endothelial dysfunction induced by adipokine visfatin,” Cardiovascular Research, vol. 89, no. 2, pp. 401–409, 2011. View at Publisher · View at Google Scholar · View at Scopus
  108. Q. Huang, Y. Guo, H. Zeng, W. Xie, H. Yan, and H. Ding, “Visfatin stimulates a cellular renin-angiotensin system in cultured rat mesangial cells,” Endocrine Research, vol. 36, no. 3, pp. 93–100, 2011. View at Publisher · View at Google Scholar · View at Scopus
  109. C. A. Chiu, T. H. Yu, W. C. Hung et al., “Increased expression of visfatin in monocytes and macrophages in male acute myocardial infarction patients,” Mediators of Inflammation, vol. 2012, Article ID 469852, 7 pages, 2012. View at Publisher · View at Google Scholar
  110. E. Oviedo-Orta, A. Bermudez-Fajardo, S. Karanam, U. Benbow, and A. C. Newby, “Comparison of MMP-2 and MMP-9 secretion from T helper 0, 1 and 2 lymphocytes alone and in coculture with macrophages,” Immunology, vol. 124, no. 1, pp. 42–50, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. H. K. Song, M. H. Lee, B. K. Kim et al., “Visfatin: a new player in mesangial cell physiology and diabetic nephropathy,” American Journal of Physiology, vol. 295, no. 5, pp. 1485–1494, 2008. View at Google Scholar
  112. D. J. Hausenloy and D. M. Yellon, “The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion,” Journal of Molecular and Cellular Cardiology, vol. 35, no. 4, pp. 339–341, 2003. View at Publisher · View at Google Scholar · View at Scopus
  113. C. P. Hsu, S. Oka, D. Shao, N. Hariharan, and J. Sadoshima, “Nicotinamide phosphoribosyltransferase regulates cell survival through nad+ synthesis in cardiac myocytes,” Circulation Research, vol. 105, no. 5, pp. 481–491, 2009. View at Publisher · View at Google Scholar · View at Scopus
  114. S. Y. Lim, S. M. Davidson, A. J. Paramanathan, C. C. T. Smith, D. M. Yellon, and D. J. Hausenloy, “The novel adipocytokine visfatin exerts direct cardioprotective effects,” Journal of Cellular and Molecular Medicine, vol. 12, no. 4, pp. 1395–1403, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. P. Wang, T. Xu, Y. Guan et al., “Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway,” Annals of Neurology, vol. 69, no. 2, pp. 360–374, 2011. View at Publisher · View at Google Scholar · View at Scopus
  116. C. Rask-Madsen and G. L. King, “Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes,” Nature Clinical Practice Endocrinology & Metabolism, vol. 3, no. 1, pp. 46–56, 2007. View at Publisher · View at Google Scholar
  117. H. Yamawaki, N. Hara, M. Okada, and Y. Hara, “Visfatin causes endothelium-dependent relaxation in isolated blood vessels,” Biochemical and Biophysical Research Communications, vol. 383, no. 4, pp. 503–508, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. H. K. Song, M. H. Lee, B. K. Kim et al., “Visfatin: a new player in mesangial cell physiology and diabetic nephropathy,” American Journal of Physiology, vol. 295, no. 5, pp. 1485–1494, 2008. View at Publisher · View at Google Scholar
  119. N. Busso, M. Karababa, M. Nobile et al., “Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD,” PLoS One, vol. 3, no. 5, Article ID e2267, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. F. Montecucco, I. Bauer, V. Braunersreuther et al., “Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction,” Antioxidants & Redox Signaling, vol. 18, no. 6, pp. 630–641, 2013. View at Google Scholar
  121. C. Jacques, M. Holzenberger, Z. Mladenovic et al., “Proinflammatory actions of visfatin/nicotinamide phosphoribosyltransferase (Nampt) involve regulation of insulin signaling pathway and Nampt enzymatic activity,” Journal of Biological Chemistry, vol. 287, no. 18, pp. 15100–15108, 2012. View at Publisher · View at Google Scholar
  122. R. M. Touyz, “Lipid rafts take center stage in endothelial cell redox signaling by death receptors,” Hypertension, vol. 47, no. 1, pp. 16–18, 2006. View at Publisher · View at Google Scholar · View at Scopus
  123. J. Xiao, B. Sun, M. Li et al., “A novel adipocytokine visfatin protects against H2O2 -induced myocardial apoptosis: a missing link between obesity and cardiovascular disease,” Journal of Cellular Physiology, vol. 228, no. 3, pp. 495–501, 2012. View at Google Scholar
  124. G. Iacobellis, F. Assael, M. C. Ribaudo et al., “Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction,” Obesity Research, vol. 11, no. 2, pp. 304–310, 2003. View at Google Scholar · View at Scopus
  125. G. Iacobellis, M. C. Ribaudo, F. Assael et al., “Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 11, pp. 5163–5168, 2003. View at Publisher · View at Google Scholar · View at Scopus
  126. M. R. Williams, N. Kataoka, Y. Sakurai, C. M. Powers, S. G. Eskin, and L. V. McIntire, “Gene expression of endothelial cells due to interleukin-1 beta stimulation and neutrophil transmigration,” Endothelium, vol. 15, no. 1-2, pp. 73–84, 2008. View at Publisher · View at Google Scholar · View at Scopus